Gapping up
In reaction to earnings/guidance:
- SNX +4.8%, CMTL +2.8%, PENN +1.4% (also comments on Barstool Sportsbook launch progress), SHW +0.6%
Other news:
- ETON +10.1% (receives FDA Approval of Orphan Drug ALKINDI SPRINKLE)
- CRDF +8.2% (prices offering of 6,500,000 shares of its common stock at $13.50 per share)
- CVAC +8.2% (first participant dosed in a Phase 2a COVID trial)
- SRGA +8% (to acquire Holo Surgical and its ARAI Digital Surgery Platform)
- EGBN +7.6% (reinstates share repurchase program)
- MRNA +3.4% (announces publication in NEJM of interim results from older cohorts in Phase 1 study of COVID-19 vaccine)
- NKLA +2% (GM extends talks after fraud, sexual assault allegations surface, according to CNBC)
- REGN +1.8% (announces REGN-COV2 antibody cocktail reduced viral levels in COVID-19 patients)
- CZR +1.4% (to acquire William Hill for £2.9 bln)
- ALNY +1.4% (announced positive topline results from the ILLUMINATE-B pediatric Phase 3 study of lumasiran for the treatment of primary hyperoxaluria type 1)
- HTHT +1.1% (issues response to additional short seller report)
Analyst comments:
- ACHC +4.5% (upgraded to Strong Buy from Outperform at Raymond James)
- GOOS +2.7% (upgraded to Outperform from Market Perform at Cowen)
- HAS +2.2% (upgraded to Buy from Hold at Stifel)
- PII +2.2% (upgraded to Buy from Neutral at Longbow)
- AZEK +1.8% (upgraded to Buy from Neutral at Goldman)
- SHOP +1.5% (upgraded to Outperform from Neutral at Wedbush)
- SR +1.5% (upgraded to Buy from Hold at Stifel)
- HUN +1.4% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- SBUX +1.4% (upgraded to Outperform from Market Perform at Cowen)
- TWO +1.2% (upgraded to Outperform from Mkt Perform at Raymond James)